Development of novel oligomer-based intravascular contrast agents for MRI using gadolinium chelates

190 p.Contrast agents with high relaxivity are needed for increasing the sensitivity of magnetic resonance imaging (MRI) for novel clinical and research applications. Therefore, we are developing a new class of oligomer-based contrast agents by incorporating multiple-gadolinium complexes into peptides of controlled length and structure. This allows synthesis of a library of Gd-peptides with different sequences, peptide length and number of Gd-chelates. Screening this library will enable selection of oligomers with desired properties.DOCTOR OF PHILOSOPHY (SPMS